Immunogenicity and safety of high-dose versus double-dose quadrivalent inactivated influenza vaccine in adult kidney transplant recipients: A randomized control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230510005

Enrollment

120

Registered

2023-05-10

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplant recipients Immunogenicity, safety, immunocompromised, solid organ transplant recipients

Interventions

Adult kidney transplant recipients randomly receive high-dose quadrivalent inactivated influenza vaccine for 1 dose. check immunogenicity before and 4 weeks after the dose.,Adult kidney transplant r

Experimental Biological/Vaccine,Active Comparator Biological/Vaccine

High-dose quadrivalent inactivated influenza vaccine,Double-dose quadrivalent inactivated influenza vaccine

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult kidney transplant recipients (age > 15 years old) who receive immunosuppressive agents at least 3 months

Exclusion criteria

Exclusion criteria: Adult kidney transplant recipients (age > 15 years old) who receive influenza vaccination within 6 months

Design outcomes

Primary

Measure	Time frame
Immunogenicity 4 weeks Heagglutination inhibition titer	—

Secondary

Measure	Time frame
Adverese events 3 and 7 days Local and systemic adverese events	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jackrapong.brm@mahidol.ac.th022011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026